Lu, T. M. et al. Effect of rosuvastatin on plasma levels of asymmetric dimethylarginine in patients with hypercholesterolemia. The American journal of cardiology 94, 157–161, doi: 10.1016/j.amjcard.2004.03.052 (2004).

Depending on which press report one reads, the presence of contaminant was either discovered by the manufacturer during process optimization, or by Novartis’ generic drugs subsidiary Sandoz, during routine raw material testing (13). 

Looks like strength training shouldn’t be ignored. A very recent study out of Sydney looked at 80000 people and found that twice a week strength training of any sort reduced all cause mortality by23% and cancer deaths by 31%,while aerobic training had more of an effect on heart disease. Journal of Epidemiology 2017 Stomatakis et. al.

激素治疗市场以9.8%的复合增速自2004年的63亿美元成长为2008年的91亿美元。 增长主要来自于主导产品Casodex, Zoladex, Aromasin, Femara 和 Arimidex的销售增长。

NOTE: Richard Wurtman, mentioned in the articles, was also the developer of the “Fen” half of Fen-Phen, the miracle diet drug which became another disaster from unintended consequences. content.time.com /time/subscriber /article/0,33009,985187-4,00.html

Antisoma (LSE:ASM.L) is a biotechnology company specialising in the development of novel drugs for the treatment of cancer. Antisoma has a diverse portfolio of drugs in development

Greek were great philosophers and great mathematicians. In particular, they made the fantastic discovery that the square root of 2 cannot be a rational number. Probably the first mathematical proof by contradiction in the history.

Preventing situations like this from occurring in the future will be complex, Fuglsang notes, given the different players involved—from the pharmacopeias, which set standards for the APIs and excipients, to the regulatory agencies, whose guidelines refer to the pharmacopeias and standards for development, to finished drug manufacturers who buy API and excipients from subcontractors, to subcontractors who make the API, and the national testing labs, which test products to ensure that they meet standards.

        (d)   Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

Our operating history is limited to pre-clinical and clinical development of one product, and our operations to date have been limited primarily to research and development, raising capital and recruiting scientific and management personnel and third-party partners. Therefore, it may be difficult to evaluate our business and prospects. We have not yet demonstrated an ability to commercialize or obtain regulatory approval for any product candidate. Consequently, any predictions about our future performance may not be accurate, and you may not be able to fully assess our ability to complete development and/or commercialize Aramchol, and any future product candidates, obtain regulatory approvals or achieve market acceptance or favorable pricing for Aramchol and any future product candidates.

One of our audit committee’s main roles is to assist the board of directors in fulfilling its responsibility for oversight of the quality and integrity of the accounting, auditing and reporting practices of the Company. The audit committee oversees the appointment, compensation, and oversight of the public accounting firm engaged to prepare or issue an audit report on the financial statements of the Company. Our Board has delegated to the audit committee the power to pre-approve non-auditing services rendered by the Company’s independent auditors without the need for further approval by the board of directors. As such, our audit committee have adopted a pre-approval policy for the engagement of our independent registered public accounting firm to perform certain audit and non-audit services. Pursuant to this policy, which is designed to assure that such engagements do not impair the independence of our auditors, the audit committee pre-approves annually a list of specific audit and non-audit services in the categories of audit services, audit-related services, tax services and other services that may be performed by our independent registered public accounting firm. The last pre-approval policy was adopted by our audit committee on March 10, 2019 for a period of twelve months. Since its establishment in May 2014, the audit committee has approved all of the audit-related fees, tax fees and all other fees. If a type of service that is to be provided by our auditors has not received such general pre-approval, it will require specific pre-approval by our audit committee. The policy prohibits retention of the independent registered public accounting firm to perform the prohibited non-audit functions defined in applicable SEC rules.

The Nasdaq Capital Market corporate governance requires each company adopting a nominating committee to certify that it has adopted a formal written charter or board resolution, as applicable, addressing the nominations process and such related matters as may be required under U.S. federal securities laws. Although not required as a foreign private issuer to adopt a nominating committee, we have decided to follow such requirement.